MedTrace Logo

Prediction Model for Response to Biologics and Small Molecular Agent for UC

NCT05186623 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-02-15

No results posted yet for this study

Summary

This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.

Conditions

Interventions

DRUG

Vedolizumab, Ustekinumab, or Tofacitinib

Drug administration and prospective follow-up for evaluating response

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-05
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05186623 on ClinicalTrials.gov